Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

VolitionRx awarded $1.5 million in non-dilutive funding

Published 2022-08-03, 08:58 a/m
Updated 2022-08-03, 10:16 a/m
© Reuters.  VolitionRx awarded $1.5 million in non-dilutive funding

© Reuters. VolitionRx awarded $1.5 million in non-dilutive funding

VolitionRx (NYSE-A:VNRX) Limited revealed that it has been awarded a further $1.5 million in non-dilutive funding from Namur Invest Capital Risk in Belgium.

The Austin, Texas-based epigenetics company said Namur Invest's award will fund an early access program for Volition's Nu.Q product portfolio at key sites across the EU, UK, and the United States.

In a statement, Volition COO Gaetan Michel said: "Thanks to this latest funding from Namur Invest, we are incredibly excited to launch our early access program and engage industry leaders in the development and adoption of our transformative Nucleosomics technology in a range of exemplifications of our assays.”

READ: VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences and Salarius Pharmaceuticals in push to develop cancer treatments

Volition applies its Nucleosomics platform to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis such as sepsis and COVID-19.

"We will be working with centers of excellence worldwide providing leading clinicians and researchers with exclusive, early access to our Nu.Q product range. This is an enormous step forward for Volition and a critical phase in our path to commercialization,” added Michel. “We would like to thank Renaud Hattiez and his team at Namur Invest for their continued support.”

Meanwhile, Renaud Hattiez, who is the director-general of Namur Invest, noted that they have supported Volition since its inception as they believe in the company's mission to revolutionize the diagnosis and monitoring of life-altering diseases.

“We are delighted to support Volition on the next step of its journey, engaging Key Opinion Leaders from across the globe and bringing Nu.Q to fruition," added Hattiez.

Namur Invest's loan is the latest grant from agencies within the Walloon Region, amounting to more than $14 million in non-dilutive funding since 2016. The new $1.5 million loan to fund Volition's early access program is unsecured, and bears interest at a rate of 6% per year and is repayable over four years with a maturity date of July 31, 2026.

Investors can learn more about Volition's Nu.Q® technology here.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter (NYSE:TWTR): @UttaraProactive

Read more on Proactive Investors CA

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.